XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer

ABSTRACT: The first phase II trial with cetuximab and FOLFOX, as 1st line therapy for MCRC, presented at ASCO 2004, showed a 81% response rate, with no unexpected toxicities for the combination. This study is aimed at establishing the efficacy and safety of the combination cetuximab/XELOX as first line therapy in patients with MCRC.

DISEASE(S): Colorectal Carcinoma,Colorectal Neoplasms

PROVIDER: 2020680 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR